(MedPage Today) — Iptacopan (Fabhalta) slowed kidney function decline in adults with immunoglobulin A (IgA) nephropathy, according to final data from the phase III APPLAUSE-IgAN study.
The study met its primary endpoint, showing an annualized…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
